Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial

被引：0

作者：

Marzo-Ortega, Helena ^{[1
]}

Miceli-Richard, Corinne ^{[2
]}

Gill, Sonja ^{[3
]}

Magrey, Marina ^{[4
]}

Machado, Paula ^{[5
]}

Shete, Abhijit ^{[6
]}

Wang, Jianyuan ^{[6
]}

Rohrer, Susanne ^{[6
]}

Deodhar, Atul ^{[7
]}

机构：

[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, NIHR Leeds Biomed Res Ctr, Leeds Teaching Hosp Trust, Leeds, W Yorkshire, England

[2] Paris Descartes Univ, Hop Cochin, AP HP, Dept Rheumatol, Paris, France

[3] 412 3075 Hosp Gate, Oakville, ON, Canada

[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] Novartis Pharma AG, Basel, Switzerland

[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0364

引用

页数：3

共 18 条

[1] Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Marzo-Ortega, Helena
Miceli-Richard, Corinne
Gill, Sonja
Magrey, Marina
Machado, Paula
Shete, Abhijit
Wang, Jianyuan
Rohrer, Susanne
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[2] SUBCUTANEOUS SECUKINUMAB 150MG PROVIDES RAPID AND SUSTAINED RELIEF IN TOTAL AND NOCTURNAL BACK PAIN, MORNING STIFFNESS AND FATIGUE IN PATIENTS WITH ACTIVE AS OVER 4 YEARS
Marzo-Ortega, Helena
Miceli-Richard, Corinne
Gill, Sonja
Magery, Marina
Machado, Paula G. P.
Shete, Abhijit
Wang, Jianyuan
Rohrer, Susanne
Deodhar, Atul
RHEUMATOLOGY, 2020, 59 : 113 - 113
[3] 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial
Marzo-Ortega, Helena
Sieper, Joachim
Kivitz, Alan J.
Blanco, Ricardo
Cohen, Martin
Pavelka, Karel
Delicha, Eumorphia M.
Stefanska, Anna
Richards, Hanno B.
Rohrer, Susanne
LANCET RHEUMATOLOGY, 2020, 2 (06): : E339 - E346
[4] LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
Marzo-Ortega, Helena
Sieper, Joachim
Kivitz, Alan
Blanco, Ricardo
Cohen, Martin
Pavelka, Karel
Delicha, Eumorphia Maria
Stefanska, Anna
Richards, Hanno
Rohrer, Susanne
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 873 - 873
[5] LONG-TERM EVALUATION OF SECUKINUMAB 150MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
Beake, Jess
RHEUMATOLOGY, 2020, 59 : 144 - 144
[6] SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 4-YEAR RESULTS FROM THE PHASE III TRIAL, MEASURE 2
Marzo-Ortega, H.
Sieper, J.
Kivitz, A.
Blanco, R.
Cohen, M.
Delicha, E. M.
Rohrer, S.
Richards, H.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1005 - 1005
[7] Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study
Pavelka, Karel
Kivitz, Alan J.
Dokoupilova, Eva
Blanco, Ricardo
Maradiaga, Marco
Tahir, Hasan
Wang, Yi
Porter, Brian O.
Stefanska, Anna
Richards, Hanno B.
Rohrer, Susanne
ACR OPEN RHEUMATOLOGY, 2020, 2 (02) : 119 - 127
[8] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: THREE-YEAR RESULTS FROM PHASE 3 TRIAL, MEASURE 2
Tahir, Hasan
Marzo-Ortega, Helena
Legerton, Clarence W.
Sieper, Joachim
Kivitz, Alan
Blanco, Ricardo
Cohen, Martin
Delicha, Evie Maria
Rohrer, Susanne
Richards, Hanno B.
RHEUMATOLOGY, 2018, 57
[9] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 4-YEAR RESULTS FROM THE PHASE 3 TRIAL, MEASURE 2
Marzo-Ortega, Helena
Sieper, Joachim
Kivitz, Alan
Blanco, Richardo
Cohen, Martin
Delicha, Eumorphia-Maria
Rohrer, Susanne
Richards, Hanno
RHEUMATOLOGY, 2019, 58
[10] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 3-YEAR RESULTS FROM PHASE III TRIAL, MEASURE 2
Marzo-Ortega, H.
Legerton, C. W.
Sieper, J.
Kivitz, A. J.
Blanco, R.
Cohen, M.
Delicha, E. M.
Rohrer, S.
Richards, H.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 345 - 345

← 1 2 →